|
End-of-day quote
Taipei Exchange
16/10/2026
|
5-day change | 1st Jan Change | ||
| 166.00 TWD | +1.22% |
|
-5.14% | +318.14% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 138B 4.24B 3.77B 3.5B 3.18B 6B 403B 6.1B 42.01B 16.47B 210B 15.92B 15.58B 670B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 121B 3.74B 3.33B 3.08B 2.8B 5.29B 355B 5.38B 37.05B 14.53B 185B 14.04B 13.74B 591B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.22% | ||
| 1 week | -5.14% | ||
| Current month | -12.86% | ||
| 1 month | +1.84% | ||
| 3 months | +122.52% | ||
| 6 months | +303.40% | ||
| Current year | +318.14% |
| 1 week | 155 |  | 185 |
| 1 month | 155 | | 207 |
| Current year | 33.1 | | 207 |
| 1 year | 24.7 | | 207 |
| 3 years | 7 | | 207 |
| 5 years | 7 | | 207 |
| 10 years | 2.7 | | 207 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 01/06/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 25/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 13/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 27/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 27/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.22% | -5.14% | +540.93% | +1,511.65% | 4.24B | |
| +0.43% | +6.59% | +53.41% | +103.85% | 1,120B | |
| +0.90% | -2.25% | +33.02% | +62.23% | 616B | |
| +0.71% | +3.24% | +25.81% | +93.86% | 504B | |
| -0.13% | +5.98% | +32.91% | +50.39% | 367B | |
| +0.52% | +0.24% | +73.92% | +40.15% | 360B | |
| -0.95% | +4.70% | +19.51% | +43.00% | 288B | |
| -1.98% | +3.73% | -0.86% | +13.43% | 258B | |
| -0.35% | +4.25% | +46.21% | +50.76% | 234B | |
| -0.75% | +3.32% | +32.53% | +97.21% | 194B | |
| Average | -0.04% | +2.93% | +85.74% | +206.65% | 394.51B | |
| Weighted average by Cap. | +0.13% | +3.83% | +39.72% | +72.98% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -22.94M -20.39M -18.9M -17.2M -32.45M -2.18B -32.97M -227M -89.07M -1.14B -86.09M -84.26M -3.62B | -1.36B -42M -37.34M -34.61M -31.49M -59.42M -3.99B -60.37M -416M -163M -2.08B -158M -154M -6.63B |
| Net Debt | -5.17B -159M -142M -131M -120M -226M -15.14B -229M -1.58B -619M -7.9B -599M -586M -25.18B | -16.27B -501M -446M -413M -376M -709M -47.59B -721M -4.97B -1.95B -24.84B -1.88B -1.84B -79.17B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/10/26 | NT$166.00 | +1.22% | 4,405,470 |
| 15/10/26 | NT$164.00 | -0.91% | 10,319,428 |
| 14/10/26 | NT$165.50 | -2.93% | 7,064,546 |
| 13/10/26 | NT$170.50 | -0.58% | 4,855,235 |
| 12/10/26 | NT$171.50 | -2.00% | 3,796,218 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
